Source: Virtual Congress 2021 – Therapy of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
J. Klinger (Providence, RI,, United States of America), R. Benza (Columbus, OH,, United States of America), S. Chang (Gangnam-gu, Seoul,, Republic of Korea), H. Ghofrani (Giessen,, Germany), M. Hoeper (Hannover,, Germany), P. Jansa (Prague,, Czech Republic), J. Ota-Arakaki (São Paulo,, Brazil), S. Rosenkranz (Cologne,, Germany), G. Simonneau (Le Kremlin-Bicêtre,, France), C. Vizza (Rome,, Italy), A. Vonk-Noordegraaf (Amsterdam,, Netherlands), V. Mclaughlin (Ann Arbor, MI,, United States of America). Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE. 1918

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal Source: International Congress 2017 – PAH and CTEPH Year: 2017 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis Source: International Congress 2018 – COPD management Year: 2018 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY Source: International Congress 2017 – Markers of COPD progression Year: 2017 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020